Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Upacof Paediatric is a combination oral solution developed and manufactured by Universal Corporation for the symptomatic relief of cough and respiratory congestion in children. The formulation typically combines an antihistamine with expectorant agents to address both the allergic and obstructive components of respiratory conditions. It contains diphenhydramine, which acts as a first-generation H1 receptor antagonist to reduce secretions and suppress the cough reflex, alongside ammonium chloride and sodium citrate, which serve as expectorants to thin and loosen bronchial mucus, facilitating its clearance. Menthol is often included in the formulation for its mild local anesthetic and soothing properties on the respiratory mucosa. The product is approved for pediatric use and is part of Universal Corporation's respiratory system portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Upacof Paediatric.